Fluoxetine-Conjugated Platinum (IV) prodrug-1

Fluoxetine-Conjugated Platinum (IV) prodrug-1 (Compound 8) is an eEF2K inhibitor. Fluoxetine-Conjugated Platinum (IV) prodrug-1 inhibits cancer cell proliferation, induces DNA damage, cell cycle arrest at S phase and apoptosis. Fluoxetine-Conjugated Platinum (IV) prodrug-1 induces ROS accumulation and mitochondrial dysfunction. Fluoxetine-Conjugated Platinum (IV) prodrug-1 inhibits TNBC cell migration and invasion by inhibiting MMP-2 activity. Fluoxetine-Conjugated Platinum (IV) prodrug-1 induces autophagy in TNBC cells by activating AMPK. Fluoxetine-Conjugated Platinum (IV) prodrug-1 has antitumor activity and activates immunosuppression in the 4T1-Luc mouse model. Fluoxetine-Conjugated Platinum (IV) prodrug-1 can be used in triple-negative breast cancer (TNBC) research[1].

Product Specifications

UNSPSC

12352005

Target

AMPK; Apoptosis; Autophagy; CaMK; MMP

Related Pathways

Apoptosis; Autophagy; Epigenetics; Metabolic Enzyme/Protease; Neuronal Signaling; PI3K/Akt/mTOR

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Smiles

[NH3][Pt]([NH3])(OC(CCC(N(CCC(OC1=CC=C(C=C1)C(F)(F)F)C2=CC=CC=C2)C)=O)=O)(O)(Cl)Cl

Molecular Formula

C21H28Cl2F3N3O5Pt

Molecular Weight

725.45

References & Citations

[1]Wang JQ, et al. Fluoxetine-Conjugated Platinum (IV) Prodrugs Targeting eEF2K and Conquering Multidrug Resistance against Triple-Negative Breast Cancer. J Med Chem. 2025 May 8;68 (9) :9661-9680.